%0 Journal Article
%T Immunomodulatory drugs: a promising clinical ally for cancer immunotherapy.
%A Colley A
%A Brauns T
%A Sluder AE
%A Poznansky MC
%A Gemechu Y
%J Trends Mol Med
%V 30
%N 8
%D 2024 Aug 30
%M 38821771
%F 15.272
%R 10.1016/j.molmed.2024.05.001
%X While immunomodulatory imide drugs (IMiDs) have been authorised for treatment of haematological cancers for over two decades, the appreciation of their ability to stimulate antitumour T cell and natural killer (NK) cell responses is relatively recent. Clinical trial data increasingly show that targeted immunotherapies, such as antibodies, T cells, and vaccines, improve outcomes when delivered in combination with the IMiD derivatives lenalidomide or pomalidomide. Here, we review these clinical data to highlight the relevance of IMiDs in combinatorial immunotherapy for both haematological and solid tumours. Further research into the molecular mechanisms of IMiDs and an increased understanding of their immunomodulatory effects may refine the specific applications of IMiDs and improve the design of future clinical trials, moving IMiDs to the forefront of combinatorial cancer immunotherapy.